Apixaban
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Apixaban and local guidelines before prescribing.
Mechanism
Direct factor Xa inhibitor.
Uses
Stroke prevention in non-valvular AF, treatment and prevention of VTE.
Dosing
- Apixaban | AF with non-mechanical valve disease: 5 mg twice daily; 2.5 mg twice daily only if two of: age ≥80, weight ≤60 kg, creatinine ≥133 µmol/L. Never for mechanical valves.
Cardiology: Valvular heart disease › 4.40 Drug Reference Table - Apixaban AF stroke prevention | Usually 5 mg orally twice daily; 2.5 mg twice daily if at least two of age ≥80 years, weight ≤60 kg, creatinine ≥133 micromol/L, or for NVAF with CrCl 15–29 mL/min. Check product information.
Cardiology: Cardiac Arrhythmias › 5.42 Two-Column Drug and Dose Table - Apixaban | AF: 5 mg twice daily; 2.5 mg twice daily if two of: age ≥80, weight ≤60 kg, creatinine ≥133 µmol/L.
Cardiology: Cardiomyopathies › 3.54 Common Adult Drugs and Doses - Apixaban 10 mg twice daily for 7 days, then 5 mg twice daily.
Respiratory: Emergencies
4 more dose entries from the chapters
- Apixaban PE | 10 mg twice daily for 7 days, then 5 mg twice daily.
Respiratory: Emergencies - Apixaban VTE treatment | 10 mg twice daily for 7 days, then 5 mg twice daily; after 6 months, 2.5 mg twice daily can be used for extended prevention.
Respiratory: Pulmonary Vascular Disease - Discuss long-term anticoagulation (e.g. continuing apixaban, possibly at the reduced 2.5 mg dose after 6 months).
Respiratory: Pulmonary Vascular Disease - 1. A 72-year-old on apixaban for AF needs a colonoscopy with removal of a 25 mm polyp. Creatinine clearance is 60 mL/min. Answer: High-risk procedure.
Gastroenterology: Investigations
Side effects
Bleeding, anaemia, nausea; rarely hepatic injury.
Interactions
Strong CYP3A4 and P-gp inhibitors or inducers alter levels; avoid with other anticoagulants and caution with antiplatelets.
Contraindications and cautions
Active bleeding, prosthetic valve, antiphospholipid syndrome, severe liver disease
Monitoring
Renal function, Hb, weight
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Reduce dose with criteria in AF; avoid if CrCl below 15
Overdose and reversal
Andexanet alfa or prothrombin complex concentrate for life-threatening bleeding
Special advice
Dose reduce by age, weight and renal function criteria; andexanet alfa is the reversal agent; avoid in mechanical valves and antiphospholipid syndrome.
More from the textbook: uses, cautions and other points
- Where drugs act - aspirin (COX-1), clopidogrel/prasugrel/ticagrelor (P2Y12), warfarin (vitamin K-dependent factors II, VII, IX, X), heparins (antithrombin), apixaban/rivaroxaban/edoxaban (Xa), dabigatran (thrombin), alteplase/tenecteplase (plasminogen).
Cardiology: Anatomy Physiology and Pharmacology - Factor Xa inhibitors - apixaban (twice daily), rivaroxaban (once daily with food in AF), edoxaban (once daily).
Cardiology: Anatomy Physiology and Pharmacology - Lifelong warfarin (VKA) . DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) must never be used - they caused excess valve thrombosis and stroke in trials.
Cardiology: Valvular heart disease › 4.34 Anticoagulation and Valves - A patient with a mechanical mitral valve and AF asks to switch from warfarin to apixaban. Answer: No. DOACs are contraindicated with mechanical valves; continue warfarin to the target INR (typically about 3.0 for mitral).
Cardiology: Valvular heart disease › 4.43 Exam-style Scenarios - First line (NICE NG158) for confirmed proximal DVT or PE — apixaban or rivaroxaban (no LMWH lead-in needed).
Cardiology: Venous Thromboembolism and Pulmonary Vascular Disease - First-line treatment | Apixaban or rivaroxaban
Cardiology: Venous Thromboembolism and Pulmonary Vascular Disease
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (3 mentions)
- Cardiology: Valvular heart disease (3 mentions)
- Cardiology: Cardiac Arrhythmias (1 mention)
- Cardiology: Cardiomyopathies (1 mention)
- Cardiology: Venous Thromboembolism and Pulmonary Vascular Disease (4 mentions)
- Respiratory: Emergencies (3 mentions)
- Respiratory: Pulmonary Vascular Disease (4 mentions)
- Respiratory: Sleep and Breathing (Complete) (1 mention)
- Endocrinology: Pituitary Disease (1 mention)
- Gastroenterology: Gastroenterology Emergencies (Complete) (4 mentions)
- Gastroenterology: Investigations (2 mentions)
- Neurology: Anatomy, Physiology and Pharmacology (1 mention)
- Neurology: Stroke Emergencies (2 mentions)
- Renal: Chronic Kidney Disease (1 mention)
- Haematology: Anatomy Physiology and Pharmacology (5 mentions)
- Haematology: Emergencies (1 mention)
- Haematology: Haemostasis and Thrombosis (13 mentions)
- Oncology: Emergencies (2 mentions)
- ENT: Emergencies (2 mentions)
- Ophthalmology: Red emergencies (1 mention)
- Surgery: Surgical principles and perioperative care (5 mentions)
- Surgery: Major trauma and burns (1 mention)
- Surgery: Acute abdomen and emergency general surgery (1 mention)
- Medicine of the older adult.: Falls, syncope, mobility and fragility fractures (1 mention)
- Medicine of the older adult: .Prescribing and deprescribing in older people (4 mentions)